AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19376585 — intervention group
Group type: COMPARATOR
Intervention: Macular photocoagulation (MPC)
Number of subjects: 150
Study 17550489 — intervention group
Group type: EXPERIMENTAL
Intervention: Menevit antioxidant (one capsule per day for three months)
Number of subjects: 60
Study 17550489 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical in appearance to Menevit, one capsule per day for three months)
Number of subjects: 60
Study 17550489 — intervention group
Group type: EXPERIMENTAL
Intervention: Menevit antioxidant
Number of subjects: 60
Study 17550489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15370021 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Intervention Group (AIG) - four sessions
Number of subjects: 34
Study 15370021 — intervention group
Group type: COMPARATOR
Intervention: Control group - no treatment
Number of subjects: 34
Study 15370021 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Intervention Group (AIG)
Number of subjects: 34
Study 11598393 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral folate (5 mg/day)
Number of subjects: 66
Study 11598393 — intervention group
Group type: COMPARATOR
Intervention: No vitamin supplementation (control group)
Number of subjects: 66
Study 9688014 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous fluconazole at 200 mg/day
Number of subjects: 68
Study 9688014 — intervention group
Group type: COMPARATOR
Intervention: Intermittent therapy at the time of symptomatic relapses
Number of subjects: 68
Study 9688014 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (up to 800 mg/day)
Number of subjects: 68
Study 7805084 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy (80 to 325 mg of aspirin) before the procedure
Number of subjects: 0
Study 7805084 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic therapy with heparin for 1 or more days before angioplasty
Number of subjects: 0
Study 7805084 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended heparin therapy after thrombus or coronary dissection
Number of subjects: 0
Study 7805084 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody inhibitors to platelet membrane glycoprotein IIb/IIIa
Number of subjects: 0
Study 7805084 — intervention group
Group type: EXPERIMENTAL
Intervention: More potent and specific antithrombin and antiplatelet agents
Number of subjects: 0
Study 7805084 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific platelet IIb/IIIa inhibitors, hirudin, hirulog, and factor Xa inhibitors
Number of subjects: 0
Study 2492709 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 0
Study 338851 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCT)
Number of subjects: 79
Study 338851 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (SP)
Number of subjects: 79
Study 338851 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCT) and Spironolactone (SP) in combination
Number of subjects: 79
Study 338851 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCT) and Spironolactone (SP)
Number of subjects: 79
Study 30908472 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using verteporfin as the photosensitizing agent, repeated every 3 months up to a maximum of 6 treatments.
Number of subjects: 41
Study 31445198 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus panitumumab (group A)
Number of subjects: 164
Study 31445198 — intervention group
Group type: COMPARATOR
Intervention: 5-FU/LV plus panitumumab (group B)
Number of subjects: 164
Study 27548910 — intervention group
Group type: EXPERIMENTAL
Intervention: sLMA (LMA group)
Number of subjects: 40
Study 27548910 — intervention group
Group type: COMPARATOR
Intervention: ETT (ETT group)
Number of subjects: 40
Study 25847900 — intervention group
Group type: EXPERIMENTAL
Intervention: cinacalcet in combination with potassium citrate and allopurinol
Number of subjects: 10
Study 25847900 — intervention group
Group type: COMPARATOR
Intervention: potassium citrate and allopurinol (control)
Number of subjects: 10
Study 23556995 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Frequency Chest Wall Oscillation (HFCWO) using the Vest® Airway Clearance System
Number of subjects: 30
Study 23556995 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional techniques of airway clearance (CPT)
Number of subjects: 30
Study 23556995 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy only (Control group)
Number of subjects: 30
Study 21410125 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration analgesia (150 mL of 300 mg ropivacaine, 30 mg ketorolac, and 500 μg epinephrine) with an additional 100 mg ropivacaine on postoperative day 1.
Number of subjects: 83
Study 21410125 — intervention group
Group type: COMPARATOR
Intervention: Control group with a single‐shot femoral nerve block (150 mg of ropivacaine with epinephrine).
Number of subjects: 83
Study 20073306 — intervention group
Group type: EXPERIMENTAL
Intervention: Kirschner tension band or screw internal fixation (Group A)
Number of subjects: 70
Study 20073306 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal fixation of locking proximal humeral plate (Group B)
Number of subjects: 70
Study 20073306 — intervention group
Group type: EXPERIMENTAL
Intervention: Humeral head replacement (Group C)
Number of subjects: 70
Study 16902175 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (4x45 seconds on the Galileo 900, 30-Hz frontal plane oscillations of 3-mm amplitude, 5 days per week for 6 weeks)
Number of subjects: 53
Study 16902175 — intervention group
Group type: COMPARATOR
Intervention: Exercise therapy on music (same amount as whole-body vibration)
Number of subjects: 53
Study 12782920 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganstigmine 12.5 mg
Number of subjects: 29
Study 12782920 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganstigmine 10 mg
Number of subjects: 29
Study 12782920 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganstigmine (5, 7.5, 10 mg)
Number of subjects: 29
Study 12782920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 12782920 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganstigmine (all doses)
Number of subjects: 29
Study 11048830 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (60 mg daily from 24 weeks' gestation through delivery)
Number of subjects: 230
Study 11048830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study 11048830 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (60 mg daily from 24 weeks' gestation through delivery) and Placebo
Number of subjects: 230
Study 9091506 — intervention group
Group type: COMPARATOR
Intervention: 0.05% tretinoin emollient cream (Renova, Retinova)
Number of subjects: 0
Study 9091506 — intervention group
Group type: COMPARATOR
Intervention: 0.05% tretinoin emollient cream (Renova, Retinova) continued for another 6 months
Number of subjects: 0
Study 9091506 — intervention group
Group type: COMPARATOR
Intervention: 0.05% tretinoin emollient cream (Renova, Retinova) after 12 months of treatment
Number of subjects: 0
Study 9091506 — intervention group
Group type: COMPARATOR
Intervention: Topical tretinoin
Number of subjects: 0
Study 8225657 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine 200 mg b.i.d.
Number of subjects: 130
Study 8225657 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 40 mg q.d.
Number of subjects: 130
Study 8225657 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 3703495 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal thrombin (100 units/ml)
Number of subjects: 28
Study 3703495 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal thrombin
Number of subjects: 28
Study 31950948 — intervention group
Group type: EXPERIMENTAL
Intervention: GTE-CUR drink (17.3 and 35.5 mg EGCG equivalent)
Number of subjects: 0
Study 30095451 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-enhanced curriculum
Number of subjects: 49
Study 30095451 — intervention group
Group type: COMPARATOR
Intervention: Standard curriculum
Number of subjects: 49
Study 27344985 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of Untreated Psychosis (DUP)
Number of subjects: 122
Study 24561340 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride releasing glass ionomer cement (GC Fuji Ortho LC)
Number of subjects: 20
Study 24561340 — intervention group
Group type: COMPARATOR
Intervention: Conventional composite (Transbond XT)
Number of subjects: 20
Study 24561340 — intervention group
Group type: EXPERIMENTAL
Intervention: Both adhesive types
Number of subjects: 20
Study 22800353 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultracision-harmonic scalpel
Number of subjects: 88
Study 22800353 — intervention group
Group type: COMPARATOR
Intervention: Conventional tonsillectomy (control)
Number of subjects: 88
Study 20169667 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus carboplatin (TC) therapy: 180 mg/m2 paclitaxel on day 1 plus AUC 6 mg/mL x minute carboplatin on day 1 every 21 days
Number of subjects: 99
Study 20169667 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan plus cisplatin (CPT-P) therapy: 60 mg/m2 irinotecan hydrochloride on days 1, 8, 15 plus 60 mg/m2 cisplatin on day 1 every 28 days
Number of subjects: 99
Study 20169667 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression-free survival (PFS)
Number of subjects: 99
Study 18286417 — intervention group
Group type: EXPERIMENTAL
Intervention: Dropping flashcards as a study method
Number of subjects: 0
Study 18286417 — intervention group
Group type: COMPARATOR
Intervention: Using flashcards without dropping items
Number of subjects: 0
Study 12573174 — intervention group
Group type: EXPERIMENTAL
Intervention: Accord
Number of subjects: 20
Study 12573174 — intervention group
Group type: EXPERIMENTAL
Intervention: Eclipse
Number of subjects: 20
Study 12573174 — intervention group
Group type: EXPERIMENTAL
Intervention: Own brand
Number of subjects: 20
Study 12573174 — intervention group
Group type: COMPARATOR
Intervention: Denicotinized tobacco cigarettes
Number of subjects: 20
Study 9726692 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.3 mg
Number of subjects: 0
Study 9726692 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 60 mg
Number of subjects: 0
Study 9726692 — intervention group
Group type: COMPARATOR
Intervention: Combination treatment (cerivastatin and nifedipine)
Number of subjects: 0
Study 7527108 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril 2 mg once daily
Number of subjects: 161
Study 7527108 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine slow-release (SR) 20 mg twice daily
Number of subjects: 161
Study 7527108 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of trandolapril and nifedipine SR
Number of subjects: 161
Study 7527108 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine SR
Number of subjects: 161
Study 2662743 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol, 50 to 200 mg once daily
Number of subjects: 39
Study 2662743 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine, 10 to 30 mg 3 times daily
Number of subjects: 39
Study 2662743 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 39
Study 2662743 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 39
Study 30418099 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-Incision and One-Puncture Laparoscopic Appendectomy (SIOPLA)
Number of subjects: 72
Study 30418099 — intervention group
Group type: COMPARATOR
Intervention: Conventional Three-Port Laparoscopic Appendectomy (CLA)
Number of subjects: 72
Study 28111980 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise for 12 months
Number of subjects: 137
Study 26412801 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-bioavailability BNX sublingual tablet
Number of subjects: 758
Study 26412801 — intervention group
Group type: COMPARATOR
Intervention: Generic buprenorphine
Number of subjects: 758
Study 26412801 — intervention group
Group type: COMPARATOR
Intervention: BNX film
Number of subjects: 758
Study 23797603 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegaptanib DHPC + MEB e-mail (Intervention group, N = 110)
Number of subjects: 215
Study 23797603 — intervention group
Group type: COMPARATOR
Intervention: Traditional paper-based DHPC only (Control group, N = 105)
Number of subjects: 215
Study 21453657 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue pre-expansion
Number of subjects: 29
Study 21453657 — intervention group
Group type: COMPARATOR
Intervention: Control (unexpanded radial forearm free flap donor site skin)
Number of subjects: 29
Study 19556972 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren monotherapy
Number of subjects: 0
Study 19556972 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren combination therapy
Number of subjects: 0
Study 19556972 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren monotherapy or combination therapy
Number of subjects: 0
Study 16681573 — intervention group
Group type: EXPERIMENTAL
Intervention: Bath PUVA (n = 9)
Number of subjects: 33
Study 16681573 — intervention group
Group type: EXPERIMENTAL
Intervention: MD-UVA1 (n = 11)
Number of subjects: 33
Study 16681573 — intervention group
Group type: COMPARATOR
Intervention: NB-UVB (n = 13)
Number of subjects: 33
Study 15517078 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg three times daily for 4 weeks)
Number of subjects: 19
Study 15517078 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 women, same age range as PCOS women)
Number of subjects: 19
Study 15517078 — intervention group
Group type: COMPARATOR
Intervention: PCOS women (untreated)
Number of subjects: 19
Study 11781669 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin A (200,000 IU) on admission and placebo daily until discharge
Number of subjects: 900
Study 11781669 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose vitamin A (5,000 IU) daily from admission until discharge
Number of subjects: 900
Study 11781669 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily from admission until discharge
Number of subjects: 900
Study 9264493 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine (5 mg BID)
Number of subjects: 450
Study 9264493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 8496306 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tryptophan depletion
Number of subjects: 8
Study 8496306 — intervention group
Group type: COMPARATOR
Intervention: Sham tryptophan depletion
Number of subjects: 8
Study 31503155 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin 100 mg daily
Number of subjects: 154
Study 31503155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 28850380 — intervention group
Group type: EXPERIMENTAL
Intervention: Combat system (computerized clinical decision support tool)
Number of subjects: 214
Study 28850380 — intervention group
Group type: COMPARATOR
Intervention: Paper-and-pencil method (control group)
Number of subjects: 214
Study 25346093 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol/betamethasone dipropionate topical gel (once daily for 8 weeks)
Number of subjects: 1795
Study 23001413 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-butanol (40 mg)
Number of subjects: 0
Study 23001413 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath test for adherence monitoring
Number of subjects: 0
Study 23001413 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-butanol ingestion
Number of subjects: 0
Study 23001413 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue application of 2-butanol
Number of subjects: 0
Study 21972410 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control with gliclazide modified release targeting HbA1c of ≤6.5%
Number of subjects: 11140
Study 19345789 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated foot orthoses made from EVA for 8 weeks
Number of subjects: 142
Study 19345789 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized foot orthoses made from EVA for 8 weeks
Number of subjects: 142
Study 16461832 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior LA ablation patients
Number of subjects: 15
Study 16461832 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 15
Study 15253730 — intervention group
Group type: EXPERIMENTAL
Intervention: Early treatment with erythropoietin alpha (50 U/kg/wk)
Number of subjects: 88
Study 15253730 — intervention group
Group type: COMPARATOR
Intervention: Deferred treatment (erythropoietin initiated when hemoglobin <9 g/dL)
Number of subjects: 88
Study 11817199 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthwise Communities Project (HCP) - includes distribution of the Healthwise Handbook, telephone advice line, and website.
Number of subjects: 0
Study 11817199 — intervention group
Group type: COMPARATOR
Intervention: Control communities (comparison communities)
Number of subjects: 0
Study 9385487 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily (QD) formulation of loratadine 10 mg and pseudoephedrine sulfate 240 mg
Number of subjects: 24
Study 9385487 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily (BID) formulation of loratadine 5 mg and pseudoephedrine sulfate 120 mg
Number of subjects: 24
Study 8100153 — intervention group
Group type: EXPERIMENTAL
Intervention: UDCA 600 mg/day for 3 months
Number of subjects: 19
Study 8100153 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 19
Study 8100153 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term UDCA treatment (mean 20 months)
Number of subjects: 19
Study 3548493 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (200 mg intravenous)
Number of subjects: 10
Study 3548493 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline solution (placebo)
Number of subjects: 10
Study 29538579 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 60
Study 29538579 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 60
Study 27496232 — intervention group
Group type: EXPERIMENTAL
Intervention: calcifediol 0.266 mg capsules for 15 days
Number of subjects: 144
Study 27496232 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 144
Study 27496232 — intervention group
Group type: EXPERIMENTAL
Intervention: calcifediol
Number of subjects: 144
Study 24241495 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron loading (1.25 mg/kg iron sucrose)
Number of subjects: 30
Study 24241495 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron chelation therapy (30 mg/kg deferasirox)
Number of subjects: 30
Study 24241495 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 24241495 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron sucrose
Number of subjects: 30
Study 24241495 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 30
Study 24241495 — intervention group
Group type: EXPERIMENTAL
Intervention: Labile plasma iron
Number of subjects: 30
Study 21300466 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant cisplatin and hyperfractionated radiotherapy (cisplatin 20 mg/m² for 5 consecutive days during weeks 1 and 5, median total dose 74.4 Gy; 1.2 Gy twice daily; 5 days per week)
Number of subjects: 224
Study 21300466 — intervention group
Group type: COMPARATOR
Intervention: Hyperfractionated radiotherapy alone (median total dose, 74.4 Gy; 1.2 Gy twice daily; 5 days per week)
Number of subjects: 224
Study 20147896 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipranavir/ritonavir (TPV/r) 500 mg/200 mg b.i.d.
Number of subjects: 23
Study 20147896 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple dosing of TPV/r
Number of subjects: 23
Study 17907263 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.75 mg ST zolpidem
Number of subjects: 24
Study 17907263 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 mg ST zolpidem
Number of subjects: 24
Study 17907263 — intervention group
Group type: COMPARATOR
Intervention: 1 mg ST zolpidem
Number of subjects: 24
Study 17907263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 16756690 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light (10,000 lux)
Number of subjects: 118
Study 16756690 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory stimuli (60 dB)
Number of subjects: 118
Study 16756690 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density negative ions (4.5x10(14) ions/s)
Number of subjects: 118
Study 16756690 — intervention group
Group type: COMPARATOR
Intervention: Low-density negative ions (1.7x10(11) ions/s; placebo control)
Number of subjects: 118
Study 14663041 — intervention group
Group type: EXPERIMENTAL
Intervention: riluzole 200 mg/day
Number of subjects: 63
Study 14663041 — intervention group
Group type: EXPERIMENTAL
Intervention: riluzole 100 mg/day
Number of subjects: 63
Study 14663041 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 63
Study 11054627 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 20
Study 11054627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8864970 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatment mainly using spinal manipulation
Number of subjects: 59
Study 1378155 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25-50 mg once daily, starting at 12.5 mg for 2 days)
Number of subjects: 99
Study 1378155 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50-100 mg once daily, starting at 50 mg)
Number of subjects: 99
Study 6700642 — intervention group
Group type: EXPERIMENTAL
Intervention: Tonsillectomy or tonsillectomy with adenoidectomy
Number of subjects: 187
Study 6700642 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical treatment
Number of subjects: 187
Study 6700642 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 187
Study 31661015 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation screening trial
Number of subjects: 0
Study 31661015 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29093302 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring device for urinary sodium-to-potassium ratio
Number of subjects: 92
Study 29093302 — intervention group
Group type: COMPARATOR
Intervention: Control group (no device)
Number of subjects: 92